COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.
Executives at the biggest COVID vaccine makers including Pfizer Inc PFE.N and Moderna Inc MRNA.O said they believe most people who wanted to get vaccinated against COVID have already done so - more than 5 billion people worldwide.
In the coming year, most COVID vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said.
Pfizer, which makes its shot with Germany's BioNTech SE 22UAy.DE, and Moderna still see a major role for themselves in the vaccine market even as overall demand declines.
Upstart U.S. vaccine maker Novavax Inc NVAX.O and Germany's CureVac NV 5CV.DE, which is working with GlaxoSmithKline GSK.L, are developing vaccines they hope to target at the booster market.
The roles of AstraZeneca Plc AZN.L and Johnson & Johnson JNJ.N, whose shots have been less popular or effective, are expected to decline in this market.
"It becomes a very competitive game with companies battling it out with pricing and for market share, even for vaccines that are considered to be the best, like Pfizer and Moderna," said Hartaj Singh, an analyst at Oppenheimer & Co.
It is not known yet how many booster doses will be needed. Second booster shots are currently recommended in some countries for only a subset of the population.
It is also unclear if vaccine makers will sell a redesigned shot this fall and each fall afterward, as flu vaccine makers do to match circulating strains, and what impact that might have on waning demand.
Pfizer Chief Executive Albert Bourla said in an interview that adults who are still unvaccinated are unlikely to seek out shots now, more than two years into the pandemic.
It will be the “already vaccinated” who account for demand, Bourla said.
Moderna executives recently said those who would benefit from annual boosting include people over 50 and adults with other health risk factors or high-risk occupations, including healthcare workers.
Moderna CEO Stephane Bancel estimated this population to be around 1.7 billion people, or some 21% of the global population.
Moderna and Pfizer/BioNTech, which make messenger RNA vaccines that can be updated somewhat quicker than those from competitors, said they are developing vaccines targeting the Omicron variant of the virus.
The United States and Western Europe - where about 600 million people are vaccinated - will remain important markets, but sales may be a fraction of what they have been, Cowen analyst Tyler Van Buren said.
"The low hanging fruit is that 20%-25% of people who are so-called high risk for various reasons, and I think that is the population that is most likely to get it every year," he said.
That would be significantly less than the roughly 49% of adults in the United States and 62% of adults in Europe who have received at least one booster so far, or about 335 million people.
Analysts have forecast revenue of over $17 billion for the Pfizer/BioNTech shot and $10 billion for Moderna's in 2023, about half of the $34 billion and $23 billion they expect this year, respectively. Sales are expected to drop further from there.
THE OTHER PLAYERS
Johnson & Johnson, whose vaccine has been limited by a side effect that causes rare but sometimes fatal blood clots, declined to comment on whether it plans to push its shot as a booster in the fall. In April, the company rescinded its 2022 COVID-19 vaccine sales forecast, citing uncertainty.
South Africa's Aspen Pharmacare APNJ.J, which makes J&J's shot in Africa, warned of weak demand.
Aspen CEO Stephen Saad in an interview said, "there is going to be a place for boosters ... but it is not at the volumes you had before."
AstraZeneca CEO Pascal Soriot said in late April that its shot will still have a role in fighting the pandemic.
"We believe this vaccine still has a potential, it's very easy to administer and distribute," he said. "The volume in the future will be less because people probably will only need one booster per year and not everybody will take it."
Reuters
Tue May 10 2022
Second booster shots are currently recommended in some countries for only a subset of the population. - AP
PRK KKB: Komuniti Orang Asli perlu sokong calon PH - Ramli
Seruan itu adalah bagi mengelakkan kekeliruan dalam kalangan komuniti Orang Asli memandangkan mereka merupakan pengundi setia BN.
Malaysia manfaat platform WEF untuk suarakan kesepakatan negara-negara Islam
Datuk Seri Anwar Ibrahim menggunakan pertemuannya dengan pemimpin negara Islam bagi menyuarakan harapan agar keganasan di Gaza dihentikan.
'Geng Bob' tumpas, lima ditahan disyaki edar dadah
Kesemua suspek yang mempunyai pertalian keluarga dan aktif mengedar dadah antara enam hingga lapan bulan lalu itu ditahan jam 10.50 malam.
Anwar bertemu PM Qatar, zahirkan kesediaan Malaysia beri rawatan kepada rakyat Palestin
Perkara itu dimaklumkan oleh Anwar kepada Perdana Menteri Qatar Sheikh Mohammed bin Abdulrahman bin Jassim Al Thani pada pertemuan dua hala.
Lelaki ditahan bantu siasatan kematian pemuda Orang Asli
Suspek berusia 38 tahun itu telah memandu kenderaan dan membawa mangsa yang didakwa terkena peluru sesat ke Balai Polis Sungai Koyan.
Tourism Johor akan dikorporatkan tahun ini - Onn Hafiz
Kerajaan negeri akan mengkorporatkan Tourism Johor pada tahun ini dalam usaha untuk memperkasakan agensi berkenaan, kata Menteri Besar Johor Datuk Onn Hafiz Ghazi.
Skuad Piala Uber Malaysia pulang awal
Kemenangan tersebut menyaksikan Thailand melangkah ke suku akhir selepas mengalahkan Australia dengan keputusan sama.
Mesyuarat Khas WEF: Seruan adaptasi teknologi untuk PKS harus guna bahasa mudah
Syarikat besar mempunyai kelebihan kepakaran dan sumber yang boleh digunakan untuk membantu PKS turut sama menyertai adaptasi teknologi.
Anwar bertemu PM Pakistan dan Menteri Luar Turkiye
Kedua-dua pemimpin menyatakan komitmen untuk terus memperkukuh hubungan Putrajaya-Islamabad dan melonjakkan lagi perdagangan dua hala.
Patuhi standard pelancongan ASEAN, tarik lebih ramai pelancong - Tiong
Tiong berkata ada kecenderungan pelancong asing tidak menggunakan perkhidmatan ejen pelancongan berdaftar disebabkan kualiti yang lemah.
Vaksin COVID-19: Sarawak bincang dos penggalak hujung minggu ini
Perkara itu akan diketengahkan dalam pertemuan bersama Menteri Kesihatan Khairy Jamaluddin Abu Bakar hujung minggu ini di Kuching.
Sidang Mesyuarat Khas: Pelaksanaan 'booster dose', vaksin campuran masih dalam kajian - Khairy
Pelaksanaan dos ketiga (booster dose) dan vaksin heterologous (campuran vaksin) masih lagi dalam kajian kumpulan pakar dan akan dimaklumkan selepas ia dimuktamadkan.